검색어: fluoropyrimidines (영어 - 몰타어)

other fluoropyrimidines
fluoropyrimidines oħra

co-administration of other fluoropyrimidines with teysuno.
teħid konġunt ta' fluoropyrimidines oħra ma’ teysuno.

a minimum washout period of 7 days is recommended between administration of teysuno and other fluoropyrimidines.
perjodu minimu ta' washout ta' 7 jiem huwa rakkomandat bejn l-għoti ta' teysuno u fluoropyrimidines oħrajn.

as with other fluoropyrimidines, teysuno administration caused embryolethality and teratogenicity in animals (see section 5.3).
bħal fil-kas ta' fluoropyrimidines oħrajn, l-għoti ta' teysuno kkaġunat mewt fl-embriju u teratoġeniċità fl-annimali (ara sezzjoni 5.3).

if you receive erbitux in combination with an anticancer medicine containing fluoropyrimidines, it is more likely that you experience the following side effects of this other medicine:
jekk tirċievi erbitux flimkien ma’ mediċina kontra l-kanċer li jkun fiha fluoropyrimidines, x’aktarx li ser ikollok dawn l-effetti sekondarji li ġejjin ta’ din il-mediċina l-oħra:

for colorectal cancer these include chemotherapy based on medicines called fluoropyrimidines and treatment with other cancer medicines known as anti-vegf and anti-egfr therapies.
għall-kanċer kolorettali dawn jinkludu kimoterapija bbażata fuq mediċini li jissejħu fluoropiramidini u l-kura b’mediċini oħra tal-kanċer magħrufa bħala terapjiji kontra l-vegf u kontra l-egfr.

co-administration of other fluoropyrimidines such as capecitabine, 5-fu, tegafur, or flucytosine can lead to additive toxicities, and is contraindicated.
l-għoti fl-istess waqt ta' fluoropyrimidines oħra bħal capecitabine, 5-fu, tegafur, jew flucytosine jista' jwassal għal tossiċitajiet addittivi, u huma kontraindikati.

in repeat-dose toxicity studies, daily oral administration of capecitabine to cynomolgus monkeys and mice produced toxic effects on the gastrointestinal, lymphoid and haemopoietic systems, typical for fluoropyrimidines.
fi studji dwar it-tossiċità ta’ dożi ripetuti, l-għoti kuljum ta’ capecitabine mill-ħalq lil xadini cynomolgus u ġrieden, ipproduċew effetti tossiċi fuq is-sistema gastrointestinali, limfatika u emopoetika, tipika għal fluoropyrimidines.

are taking other fluoropyrimidine anti-cancer medicine such as fluorouracil and capecitabine, or have had severe and unexpected reactions to fluoropyrimidines have known genetic deficiency of the enzyme dihydropyrimidine dehydrogenase (dpd)
qed tieħu mediċina fluoropyrimidine oħra ta' kontra l-kanċer bħal fluorouracil u capecitabine, jew kellek reazzjonijiet severi jew mhux mistennija bi fluoropyrimidines għandek nuqqas ġenetiku tal-enzima dihydropyrimidine dehydrogenase (dpd)

history of severe and unexpected reactions to fluoropyrimidine therapy,
passat mediku ta’ reazzjonijiet serji u mhux mistennija għat-terapija bi fluoropyrimidine,